Skip to content

Calycosin triggers ferroptosis through modulation of the OTUD6B/GPX4 axis to suppress triple-negative breast cancer.

Jul 2026 · Biochemical and Biophysical Research Communications - BBRC · Vol 830, pp. 154254 · 0 citations · 33 references
Medicine

TL;DR

This is the first study to demonstrate that Cal exerts anti-TNBC activity through a novel OTUD6B/GPX4-dependent ferroptosis regulatory axis and highlights that Cal warrants further investigation as a potential candidate, and the OTUD6B/GPX4 signaling pathway may represent a significant target for TNBC treatment.

Abstract

Background

Triple-negative breast cancer (TNBC) is a clinically challenging disease subtype of breast cancer, with therapeutic outcomes remaining unsatisfactory due to its highly invasive potential. Ferroptosis, a newly identified type of programmed cell death, is mediated by the iron-dependent accumulation of lipid peroxides, presenting a potential therapeutic avenue for the treatment of TNBC. Calycosin (Cal) has demonstrated antitumor effects across various tumors; however, its therapeutic potential based on the ferroptosis pathway for TNBC treatment and the associated mechanisms remains unclear.

Methods

To achieve this, the cell counting kit-8 assay, flow cytometry assay, wound healing assay, colony formation assay, EdU assay, and xenograft mouse models were performed. Mechanisms were investigated using transcriptomic sequencing, quantitative reverse transcription polymerase chain reaction, and Western blot in vitro and in vivo.

Results

Our findings indicated that Cal significantly reduces the viability of TNBC cells, primarily manifested as suppression of growth, migration, and colony formation through the induction of ferroptosis. Additionally, Cal impairs mitochondrial function in TNBC cells by reducing mitochondrial membrane potential and elevating ferroptosis-related markers, including MDA and 4-HNE accumulation, reactive oxygen species formation, and GSH depletion. Mechanistically, Cal administration may reduce GPX4 levels through the OTUD6B-mediated ubiquitination pathway, thereby enhancing the ubiquitination and degradation of the GPX4 protein. The decreased OTUD6B and GPX4 expression significantly inhibited TNBC growth both in vivo and in vitro, resulting in ferroptosis induction in TNBC cells.

Conclusion

This is the first study to demonstrate that Cal exerts anti-TNBC activity through a novel OTUD6B/GPX4-dependent ferroptosis regulatory axis. These findings highlight that Cal warrants further investigation as a potential candidate, and the OTUD6B/GPX4 signaling pathway may represent a significant target for TNBC treatment.

View source

Similar papers

Oct 2026

Isoliquiritigenin Triggers HMOX1-Driven Ferroptosis to Suppress Non-Small Cell Lung Cancer.

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death, and new treatment strategies are needed. Ferroptosis is an iron-dependent cell death driven by lipid peroxidation, and targeting ferroptosis has become a new strategy for anti-NSCLC. Isoliquiritigenin (ISL) is a bioactive natural flav...

Yi-Jie Wang, Feng Liang, Ya-Ting Deng et al. · 0 citations
Aug 2026

Bufalin Induces Ferroptosis in Triple-Negative Breast Cancer via Inhibition of the NRF2/HO-1/GPX4 Pathway.

Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer characterized by poor prognosis and limited therapeutic options, remains a major clinical challenge. Bufalin, a principal bioactive component of Venenum Bufonis, exhibits potent anticancer activity against breast cancer. Nevertheless, th...

Ji-Ying Zhou, An-Xin Wang, M. Jin et al. · 0 citations
Open access Sep 2026

Baicalin Induces Ferroptosis in Breast Cancer Through a Novel STAT3/HO-1/GPX4 Regulatory Axis.

Multi-dimensional experiments reveal BA may regulate ferroptosis via the potential STAT3/HO-1/GPX4 signaling axis and is a promising therapeutic alternative to conventional chemotherapy, which is limited by severe systemic toxicity.

Ting-Ting Guo, Fansu Meng, De-Tang Li et al. · 0 citations
Sep 2026

Cycloechinulin inhibits breast cancer progression via the SGOL2/METTL3/ICAM2 signaling axis and suppresses the growth of breast cancer patient-derived organoids.

CCL suppresses breast cancer progression by inhibiting the novel SGOL2/METTL3/ICAM2 signaling axis and is presented as a promising natural lead compound and a novel chemical scaffold for targeted BC therapeutics.

Shuxin Liu, Bo-Ning Zeng, Dong Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.